Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362480 | 0.81 | GABRA1 (0.45) | GABRA1GABRB2CLCN2ALDH1A1LMNA | |
| SCHEMBL4599825 | 0.78 | GABRA1 (0.38) | GABRA1GABRB2ALDH1A1CACNA1CSCN5A | |
| SCHEMBL11431591 | 0.71 | MEN1 (0.36) | GABRA1GABRB2ALDH1A1LMNA | |
| SCHEMBL1362796 | 0.71 | MAOA (0.37) | GABRA1GABRB2ALDH1A1 | |
| SCHEMBL814559 | 0.70 | KDM4E (0.42) | ALDH1A1 | |
| SCHEMBL26752111 | 0.69 | ALDH1A1 (0.37) | GABRA1GABRB2ALDH1A1LMNAHTT | |
| SCHEMBL8820704 | 0.69 | GABRA1 (0.46) | GABRA1GABRB2CLCN2ALDH1A1LMNA | |
| SCHEMBL29396009 | 0.68 | GABRA1 (0.44) | GABRA1GABRB2CLCN2ALDH1A1LMNA | |
| SCHEMBL721894 | 0.68 | GABRA1 (0.44) | GABRA1GABRB2CLCN2ALDH1A1LMNA | |
| SCHEMBL28308813 | 0.67 | GABRA1 (0.45) | GABRA1GABRB2CLCN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367096-B2 | Polymers having covalently bound therapeutic agents | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20070020308-A1 | Polymers having covalently bound therapeutic agents | BOSTON SCIENTIFIC SCIMED, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2002028924-A1 | SILYL-FUNCTIONAL PSEUDO-TELECHELIC POLYISOBUTYLENE TERPOLYMERS | DOW CORNING CORPORATION (US) | 2002-04-11 | — | — | WO | disclosed |
| US-6268451-B1 | POLYMERS OF ISOBUTYLENE, ISOPRENYLPHENYL AND VINYLPHENYL WITH SILYLALKYL GROUPS WITH SOLVENTS | UNIVERSITY OF MASSACHUSETTS LOWELL | 2001-07-31 | — | — | US | disclosed |
| US-6194597-B1 | REACTING CATIONICALLY POLYMERIZABLE MONOMER(ISOBUTYLENE, ISOPRENE) WITH SILYL GROUP CONTAINING INITIATOR IN PRESENCE OF LEWIS ACID TO FORM LIVING CATIONIC POLYMER CONTAINING SILIY GROUPS | DOW CORNING CORPORATION | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020308-A1 | Polymers having covalently bound therapeutic agents | CD44, CD47, PAICS | GABRA1 2859/4885GABRB2 3061/4885CLCN2 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.